* * * * * * * * * * * * * * * STN Columbus

FILE 'HOME' ENTERED AT 13:21:19 ON 19 AUG 2003

=> file req

Uploading 09990499.str

L1STRUCTURE UPLOADED

=> s 11 full

8 SEA SSS FUL L1

=> file ca

=> s 13 full

2 L3

=> d ibib abs hitstr 1-2

ANSWER 1 OF 2 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

TITLE:

Design and pharmacology of N-[(3R)-1,2,3,4-

tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4chlorobenzyl) - 2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor

agonist

137:362928 CA

AUTHOR(S):

Sebhat, Iyassu K.; Martin, William J.; Ye, Zhixiong; Barakat, Khaled; Mosley, Ralph T.; Johnston, David B. R.; Bakshi, Raman; Palucki, Brenda; Weinberg, David H.; MacNeil, Tanya; Kalyani, Rubana N.; Tang, Rui; Stearns, Ralph A.; Miller, Randy R.; Tamvakopoulos, Constantin; Strack, Alison M.; McGowan, Erin; Cashen, Doreen E.; Drisko, Jennifer E.; Hom, Gary J.; Howard, Andrew D.; MacIntyre, D. Euan; van der Ploeg, Lex H.

T.; Patchett, Arthur A.; Nargund, Ravi P.

CORPORATE SOURCE:

Departments of Chemistry, Pharmacology, Obesity

Research, and Drug Metabolism, Merck Co. Inc., Rahway,

NJ, 07065-0900, USA

SOURCE:

Journal of Medicinal Chemistry (2002), 45(21),

4589-4593

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER:

American Chemical Society

DOCUMENT TYPE:

Journal English

LANGUAGE:

GI

AB Synthetic and natural peptides that act as nonselective melanocortin receptor agonists have been found to be anorexigenic and to stimulate erectile activity. We report the design and development of (I), a potent, selective (1184-fold vs. MC3R, 350-fold vs. MC5R), small-mol. agonist of the MC4 receptor. Pharmacol. testing confirms the food intake lowering effects of MC4R agonism and suggests another role for the receptor in the stimulation of erectile activity.

Ι

IT 312637-48-2P 312637-80-2P 475095-01-3P 475095-02-4P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (design and pharmacol. of melanocortin 4 receptor agonist)

RN 312637-48-2 · CA

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

RN 312637-80-2 CA

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 475095-01-3 CA

CN 3-Isoquinolinecarboxamide, N-[(1S)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

RN 475095-02-4 CA

CN 3-Isoquinolinecarboxamide, N-[(1S)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CA COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

134:42445 CA

TITLE:

Preparation of piperidine amino acid derivatives as

melanocortin-4 receptor agonists

INVENTOR(S): Bakshi, Raman K.; Barakat, Khaled J.; Nargund, Ravi P.; Palucki, Brenda L.; Patchett, Arthur A.; Sebhat,

Iyassu; Ye, Zhixiong; Van, Der Ploeg Leonardus H. T.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Van Der Ploeg, Leonardus H. T. SOURCE:

PCT Int. Appl., 124 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
PATENT NO.
                    KIND
                          DATE
                                         APPLICATION NO. DATE
    ------
                    ____
                          _____
                                         WO 2000074679 A1
                          20001214
                                        WO 2000-US14930 20000531
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
            CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
            ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
            MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE,
            SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
            ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
            DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
            CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                     Α1
                          20020320
                                        EP 2000-937961 20000531
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO
    JP 2003505435
                     Т2
                          20030212
                                         JP 2001-512328
                                                          20000531
    US 6350760
                      В1
                           20020226
                                         US 2000-585111
                                                          20000601
    US 2002137664
                     A1
                           20020926
                                         US 2001-990499
                                                          20011121
PRIORITY APPLN. INFO.:
                                      US 1999-137477P P
                                                         19990604
                                      US 1999-169209P P
                                                         19991202
                                      WO 2000-US14930 W 20000531
                                      US 2000-585111
                                                      A3 20000601
```

OTHER SOURCE(S): MARPAT 134:42445

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Piperidine derivs. I [R2C2 = aryl, 5- or 6-membered heteroaryl or AΒ heterocyclyl, 5- to 7-membered carbocyclyl, which may be substituted; L = (CRb2)m, where Rb = H, alkyl, (CH2)n-cycloalkyl or -aryl; m = 0-2, n = 00-3; X, Y = (CH2)0-2; Ra = H, alkyl, (CHRb)n-cycloalkyl, -aryl, -heteroaryl, -O(CHRb)naryl, which may be substituted; Re = H, alkyl, (CH2)n-aryl, -cycloalkyl, -heteroaryl, which may be substituted, acyl, sulfonyl, etc.; R1 = H, alkyl, (CH2)n-cycloalkyl, -aryl, -heteroaryl, -heterocyclyl; R2 = any group given for R1, CN, (CH2)n-carboxamido, -carboxy, -acylamino, sulfonylamino, -amino, etc.] were prepd. as agonists of the human melanocortin receptors, in particular, the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Thus, II trifluoroacetate, prepd. by coupling of Et 1-(D-4-chlorophenylalanyl)-4- $\verb|cyclohexyl-4-[(1,2,4-triazol-1-yl)methyl]| piperidine trifluoroacetate$ (prepn. given) with N-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinoline-3carboxylic acid (Boc-D-Tic), was > 2,200-fold, > 10,000-fold, and >

580-fold selective for the human MC-4R over human MC-1R, MC-2R, and MC-3R, resp.

IT 312637-48-2P 312637-49-3P 312637-81-3P 312639-77-3P 312639-78-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperidine amino acid derivs. as melanocortin-4 receptor agonists)

RN 312637-48-2 CA

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 312637-49-3 CA

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 312637-48-2 CMF C33 H41 Cl N6 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 312637-81-3 CA

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 312637-80-2 CMF C33 H41 Cl N6 O2

CM 2 ·

CRN 76-05-1 CMF C2 H F3 O2

RN 312639-77-3 CA

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-[(2,3-dihydro-3-oxo-1H-1,2,4-triazol-1-yl)methyl]-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

RN 312639-78-4 CA

CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[4-[(3-amino-1H-1,2,4-triazol-1-yl)methyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file marpat

=> s 11 full

L5 1 SEA SSS FUL L1

=> d ibib abs fqhit

ANSWER 1 OF 1 MARPAT COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 134:42445 MARPAT

TITLE: Preparation of piperidine amino acid derivatives as

melanocortin-4 receptor agonists

INVENTOR(S): Bakshi, Raman K.; Barakat, Khaled J.; Nargund, Ravi

P.; Palucki, Brenda L.; Patchett, Arthur A.; Sebhat, Iyassu; Ye, Zhixiong; Van, Der Ploeg Leonardus H. T. Merck & Co., Inc., USA; Van Der Ploeg, Leonardus H. T.

PATENT ASSIGNEE(S): PCT Int. Appl., 124 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE: FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

| | PATENT NO. | | | | KIND | | DATE | | | APPLICATION NO. | | | | | DATE | | | | | |
|------|---------------------------|------------|-----|-----|-------------|-----|------|------|----------------|-----------------|--------------------------|-----------------|------|----------|----------|------|----------|-----|--|--|
| | WO | 2000074679 | | | A1 2000 | | 2000 | 1214 | | WO 2000-US14930 | | | | 30 | 20000531 | | | | | |
| | | W: | ΑE, | AG, | AL, | AM, | AT, | AU, | AZ, | BA, | BB, | BG, | BR, | BY, | CA, | CH, | CN, | CR, | | |
| | | | | | | | | | | | | | | | GH, | | | | | |
| | | | ID, | IL, | IN, | IS, | JP, | KE, | KG, | KR, | KZ, | LC, | LK, | LR, | LS, | LT, | LU, | LV, | | |
| | | | MA, | MD, | MG, | MK, | MN, | MW, | MX, | MZ, | NO, | NZ, | PL, | PT, | RO, | RU, | SD, | SE, | | |
| | | | | | | | | | | | | | | | UZ, | | | | | |
| | | | ZW, | AM, | AZ, | BY, | KG, | KZ, | MD, | RU, | TJ, | MT | | | • | • | | • | | |
| | | RW: | GH, | GM, | KE, | LS, | MW, | MZ, | SD, | SL, | SZ, | TZ, | UG, | ZW, | AT, | BE, | CH, | CY, | | |
| | | | | | | | | | | | | | | | PT, | | | | | |
| | | | CF, | CG, | CI, | CM, | GA, | GN, | GW, | ML, | MR, | NE, | SN, | TD, | TG | | | - | | |
| | ΕP | 1187614 | | | A1 20020320 | | | | EP 2000-937961 | | | | | 20000531 | | | | | | |
| | | R: | AT, | BE, | CH, | DE, | DK, | ES, | FR, | GB, | GR, | IT, | LI, | LU, | NL, | SE, | MC, | PT, | | |
| | | | | | | | FI, | | | | | | | | | | | | | |
| | | | | | T2 20030212 | | | | | | | | | | 20000531 | | | | | |
| | US 6350760 | | | | B1 20020226 | | | | | US 2000-585111 | | | | | 20000601 | | | | | |
| | US 2002137664 A1 20020926 | | | | | | | | | | US 2001-990499 20011121 | | | | | | | | | |
| PRIO | PRIORITY APPLN. INFO.: | | | | | | | | | | US 1999-137477P 19990604 | | | | | | | | | |
| | | | | | | | | | | | US 1999-169209P 19991202 | | | | | | | | | |
| | | | | | | | | | | | | WO 2000-US14930 | | | | | 20000531 | | | |
| | | | | | | | | | | U. | S 20 | 00-5 | 8511 | 1 | 2000 | 0601 | | | | |
| GI | | | | | | | | | | | | | | | | | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Piperidine derivs. I [R2C2 = aryl, 5- or 6-membered heteroaryl or AB heterocyclyl, 5- to 7-membered carbocyclyl, which may be substituted; L = (CRb2)m, where Rb = H, alkyl, (CH2)n-cycloalkyl or -aryl; m = 0-2, n = 00-3; X, Y = (CH2)0-2; Ra = H, alkyl, (CHRb)n-cycloalkyl, -aryl, -heteroaryl, -O(CHRb) naryl, which may be substituted; Re = H, alkyl, (CH2)n-aryl, -cycloalkyl, -heteroaryl, which may be substituted, acyl, sulfonyl, etc.; R1 = H, alkyl, (CH2)n-cycloalkyl, -aryl, -heteroaryl, -heterocyclyl; R2 = any group given for R1, CN, (CH2)n-carboxamido, -carboxy, -acylamino, sulfonylamino, -amino, etc.] were prepd. as agonists of the human melanocortin receptors, in particular, the human melanocortin-4 receptor (MC-4R). They are therefore useful for the

treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Thus, II trifluoroacetate, prepd. by coupling of Et 1-(D-4-chlorophenylalanyl)-4-cyclohexyl-4-[(1,2,4-triazol-1-yl)methyl]piperidine trifluoroacetate (prepn. given) with N-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Boc-D-Tic), was > 2,200-fold, > 10,000-fold, and > 580-fold selective for the human MC-4R over human MC-1R, MC-2R, and MC-3R, resp.

MSTR 1

$$G1 = 223$$

$$G2 = C(0)$$

 $G5 = 278$

$$G21 = 287$$

$$G30 = C1$$
 $G31 = 291$

MPL: claim 1

Page 11

NTE: or pharmaceutically acceptable salts

NTE: substitution is restricted

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file uspatfull

=> s 13

L6 2 L3

=> d ibib abs hitstr 1-2

L6 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2002:251711 USPATFULL

TITLE: Substituted piperidines as melanocortin-4 receptor

agonists

INVENTOR(S): Bakshi, Raman K., Edison, NJ, UNITED STATES

Barakat, Khaled J., Brooklyn, NY, UNITED STATES
Nargund, Ravi P., East Brunswick, NJ, UNITED STATES
Palucki, Brenda L., Belle Mead, NJ, UNITED STATES
Patchett, Arthur A., Westfield, NJ, UNITED STATES

Sebhat, Iyassu, Hoboken, NJ, UNITED STATES Ye, Zhixiong, Princeton, NJ, UNITED STATES

Van Der Ploeg, Leonardus H.T., Scotch Plains, NJ,

UNITED STATES

PATENT ASSIGNEE(S): Merck & Co., Inc. (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2002137664 A1 20020926 APPLICATION INFO.: US 2001-990499 A1 20011121 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-585111, filed on 1 Jun

2000, PENDING

NUMBER DATE

PRIORITY INFORMATION: US 1999-137477P 19990604 (60)

US 1999-169209P 19991202 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907

NUMBER OF CLAIMS: 38 EXEMPLARY CLAIM: 26 LINE COUNT: 2640

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 312637-48-2P 312637-49-3P 312637-81-3P 312639-77-3P 312639-78-4P

(prepn. of piperidine amino acid derivs. as melanocortin-4 receptor agonists)

RN 312637-48-2 USPATFULL

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 312637-49-3 USPATFULL

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 312637-48-2 CMF C33 H41 C1 N6 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 312637-81-3 USPATFULL

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 312637-80-2 CMF C33 H41 C1 N6 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

CN

RN 312639-77-3 USPATFULL

3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-[(2,3-dihydro-3-oxo-1H-1,2,4-triazol-1-yl)methyl]-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

RN 312639-78-4 USPATFULL

CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[4-[(3-amino-1H-1,2,4-triazol-1-yl)methyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2002:39935 USPATFULL

TITLE:

Substituted piperidines as melanocortin-4 receptor

agonists

INVENTOR(S):

Bakshi, Raman K., Edison, NJ, United States

Barakat, Khaled J., Brooklyn, NY, United States Nargund, Ravi P., East Brunswick, NJ, United States Palucki, Brenda L., Belle Mead, NJ, United States Patchett, Arthur A., Westfield, NJ, United States

Sebhat, Iyassu, Hoboken, NJ, United States Ye, Zhixiong, Princeton, NJ, United States

Van Der Ploeg, Leonardus H. T., Scotch Plains, NJ,

United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S.

corporation)

NUMBER DATE

PRIORITY INFORMATION: US 1999-137477P 19990604 (60)

US 1999-169209P 19991202 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Seaman, D. Margaret

LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin

NUMBER OF CLAIMS: 25 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 2550

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 312637-48-2P 312637-49-3P 312637-81-3P 312639-77-3P 312639-78-4P

(prepn. of piperidine amino acid derivs. as melanocortin-4 receptor agonists)

RN 312637-48-2 USPATFULL

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

RN 312637-49-3 USPATFULL

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 312637-48-2 CMF C33 H41 C1 N6 O2

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 312637-81-3 USPATFULL

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 312637-80-2 CMF C33 H41 C1 N6 O2

Absolute stereochemistry.

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 312639-77-3 USPATFULL

CN 3-Isoquinolinecarboxamide, N-[(1R)-1-[(4-chlorophenyl)methyl]-2-[4-cyclohexyl-4-[(2,3-dihydro-3-oxo-1H-1,2,4-triazol-1-yl)methyl]-1-piperidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 312639-78-4 USPATFULL

CN 3-Isoquinolinecarboxamide, N-[(1R)-2-[4-[(3-amino-1H-1,2,4-triazol-1-yl)methyl]-4-cyclohexyl-1-piperidinyl]-1-[(4-chlorophenyl)methyl]-2-oxoethyl]-1,2,3,4-tetrahydro-, (3R)- (9CI) (CA INDEX NAME)

=> d his

(FILE 'HOME' ENTERED AT 13:21:19 ON 19 AUG 2003)

FILE 'REGISTRY' ENTERED AT 13:21:24 ON 19 AUG 2003

L1STRUCTURE UPLOADED

L2 0 S L1 SAM

L3 8 S L1 FULL

FILE 'CA' ENTERED AT 13:22:40 ON 19 AUG 2003

L42 S L3 FULL

FILE 'MARPAT' ENTERED AT 13:23:01 ON 19 AUG 2003 L5

1 S L1 FULL

FILE 'USPATFULL' ENTERED AT 13:23:26 ON 19 AUG 2003

L6 2 S L3

=>

---Logging off of STN---

Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 13:23:44 ON 19 AUG 2003